These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 26616225)

  • 21. A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Tiersten AD; Sill MW; Knight D; Muggia F; Garcia AA; Swensen R; Warshal DP; Mannel RS; Fracasso PM
    Gynecol Oncol; 2010 Sep; 118(3):303-7. PubMed ID: 20547415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.
    Power P; Stuart G; Oza A; Provencher D; Bentley JR; Miller WH; Pouliot JF
    Gynecol Oncol; 2009 Sep; 114(3):410-4. PubMed ID: 19520420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
    Katsumata N; Fujiwara Y; Kamura T; Nakanishi T; Hatae M; Aoki D; Tanaka K; Tsuda H; Kamiura S; Takehara K; Sugiyama T; Kigawa J; Fujiwara K; Ochiai K; Ishida R; Inagaki M; Noda K
    Jpn J Clin Oncol; 2008 Nov; 38(11):777-85. PubMed ID: 18927230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.
    Holloway RW; Grendys EC; Lefebvre P; Vekeman F; McMeekin S
    Oncologist; 2010; 15(10):1073-82. PubMed ID: 20930103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.
    Pothuri B; Brodsky AL; Sparano JA; Blank SV; Kim M; Hershman DL; Tiersten A; Kiesel BF; Beumer JH; Liebes L; Muggia F
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):741-751. PubMed ID: 32055930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
    Rose PG; Rodriguez M; Walker J; Greer B; Fusco N; McGuire W
    Gynecol Oncol; 2002 Apr; 85(1):136-9. PubMed ID: 11925133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
    du Bois A; Pfisterer J; Burchardi N; Loibl S; Huober J; Wimberger P; Burges A; Stähle A; Jackisch C; Kölbl H; ;
    Gynecol Oncol; 2007 Dec; 107(3):518-25. PubMed ID: 17910981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
    Kurtz JE; Kaminsky MC; Floquet A; Veillard AS; Kimmig R; Dorum A; Elit L; Buck M; Petru E; Reed N; Scambia G; Varsellona N; Brown C; Pujade-Lauraine E;
    Ann Oncol; 2011 Nov; 22(11):2417-2423. PubMed ID: 21402619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
    Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
    BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study.
    Park SJ; Kim J; Kim HS; Lee JW; Chang HK; Lee KH; Kim DY; Kim S; Chang SJ; Han SS; Park SY; Shim SH
    J Gynecol Oncol; 2020 Mar; 31(2):e15. PubMed ID: 31912673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Dizon DS; Blessing JA; Penson RT; Drake RD; Walker JL; Johnston CM; Disilvestro PA; Fader AN
    Gynecol Oncol; 2012 May; 125(2):367-71. PubMed ID: 22366594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study.
    Floquet A; Doussau A; Brouste V; Cany L; Dutin JP; Mathoulin-Pélissier S
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):61-8. PubMed ID: 24141374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
    Matulonis U; Berlin S; Lee H; Whalen C; Obermayer E; Penson R; Liu J; Campos S; Krasner C; Horowitz N
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):417-23. PubMed ID: 26119093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
    Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
    Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
    J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
    Gladieff L; Ferrero A; De Rauglaudre G; Brown C; Vasey P; Reinthaller A; Pujade-Lauraine E; Reed N; Lorusso D; Siena S; Helland H; Elit L; Mahner S
    Ann Oncol; 2012 May; 23(5):1185-1189. PubMed ID: 21976386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
    Vergote I; Schilder RJ; Pippitt CH; Wong S; Gordon AN; Scudder S; Kridelka F; Dirix L; Leach JW; Ananda S; Nanayakkara N; Melara R; Bass MB; Litten J; Adewoye H; Wenham RM
    Gynecol Oncol; 2014 Oct; 135(1):25-33. PubMed ID: 25019569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
    Tew WP; Sill MW; Walker JL; Secord AA; Bonebrake AJ; Schilder JM; Stuckey A; Rice L; Tewari KS; Aghajanian CA
    Gynecol Oncol; 2018 Nov; 151(2):257-263. PubMed ID: 30177462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
    Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD
    Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.